Merck & Company (6MK) Stock Forecast & Price Target

Compare

66 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

6MK Analyst Ratings

Moderate Buy

9 Buy

7 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Merck

& Company

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

6MK Stock 12 Month Forecast

Average Price Target

€88.56

▲(23.34%Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Merck & Company in the last 3 months. The average price target is €88.56 with a high forecast of €119.98 and a low forecast of €69.78. The average price target represents a 23.34% change from the last price of €71.80.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"64":"€64","78":"€78","92":"€92","106":"€106","120":"€120"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":119.97978204,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€119.98</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":88.5552901908,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€88.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69.77547608,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€69.78</span>\n  </div></div>","useHTML":true}}],"tickPositions":[64,78,92,106,120],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.9,73.75229092615385,77.6045818523077,81.45687277846154,85.30916370461539,89.16145463076924,93.01374555692308,96.86603648307693,100.71832740923077,104.57061833538462,108.42290926153846,112.27520018769232,116.12749111384616,{"y":119.97978204,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.9,71.33502232236924,72.77004464473846,74.2050669671077,75.64008928947692,77.07511161184615,78.51013393421539,79.94515625658461,81.38017857895385,82.81520090132307,84.2502232236923,85.68524554606154,87.12026786843076,{"y":88.5552901908,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,69.9,69.89042123692309,69.88084247384616,69.87126371076924,69.86168494769231,69.8521061846154,69.84252742153846,69.83294865846155,69.82336989538462,69.8137911323077,69.80421236923077,69.79463360615385,69.78505484307692,{"y":69.77547608,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":115.876,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.755,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.463,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.293,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.114,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.672,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.637,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.834,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.883,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.088,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.058,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.741,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€119.98

Average Price Target€88.56

Lowest Price Target€69.78

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Tim AndersonBank of America Securities

Bank of America Securities

€84.3

Buy

17.41%

Upside

Reiterated

07/23/25

Analysts Offer Insights on Healthcare Companies: Icon (NASDAQ: ICLR), Merck & Company (NYSE: MRK) and Thermo Fisher (NYSE: TMO)We reiterate our Buy rating and $99 PO on Merck (MRK).

Daina GrayboschLeerink Partners

Leerink Partners

€97.93→€78.34

Buy

9.11%

Upside

Reiterated

07/18/25

Merck & Company: Buy Rating Backed by Growth Prospects in Cardiopulmonary and Infectious Disease Franchises

Evan SeigermanBMO Capital

BMO Capital

€69.83

Hold

-2.75%

Downside

Reiterated

07/17/25

Merck & Co. Hold Rating: Balancing Promising HIV Pipeline with Competitive Challenges and Market Uncertainty

Mohit BansalWells Fargo

Wells Fargo

€82.6

Hold

15.04%

Upside

Reiterated

07/17/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Harrow Health (NASDAQ: HROW), BridgeBio Pharma (NASDAQ: BBIO) and Merck & Company (NYSE: MRK)

Vamil DivanGuggenheim

Guggenheim

€91.97

Buy

28.09%

Upside

Reiterated

07/13/25

Guggenheim Sticks to Its Buy Rating for Merck & Company (MRK)

Trung HuynhUBS

UBS

€89.41

Buy

24.53%

Upside

Reiterated

07/10/25

UBS Sticks to Their Buy Rating for Merck & Company (MRK)

Tycho PetersonJefferies

Jefferies

€117.51→€120.07

Buy

67.22%

Upside

Reiterated

07/10/25

Jefferies Sticks to Its Buy Rating for Merck & Company (MRK)

Terence FlynnMorgan Stanley

Morgan Stanley

€84.3→€83.45

Hold

16.23%

Upside

Reiterated

07/10/25

Merck & Company's Strategic Acquisition of Verona Pharma: Balancing Long-Term Gains with Short-Term Financial Adjustments

Carter GouldCantor Fitzgerald

Cantor Fitzgerald

€72.38→€70.68

Hold

-1.56%

Downside

Reiterated

07/09/25

Cantor Fitzgerald Remains a Hold on Merck & Company (MRK)

Asad HaiderGoldman Sachs

Goldman Sachs

€84.3

Buy

17.41%

Upside

Reiterated

07/09/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Courtney BreenBernstein

Bernstein

―

Hold

―

Reiterated

07/08/25

Merck & Company (MRK) Gets a Hold from Bernstein

Chris SchottJ.P. Morgan

J.P. Morgan

€110.7

Buy

54.18%

Upside

Reiterated

07/07/25

Merck & Company: Strong Growth Potential and Favorable Risk/Return Profile Amidst Keytruda's Performance and Diverse Portfolio

Luisa HectorBerenberg Bank

Berenberg Bank

€85.15

Buy

18.60%

Upside

Reiterated

07/01/25

Berenberg Bank Reaffirms Their Buy Rating on Merck & Company (MRK)

Steve ScalaTD Cowen

TD Cowen

€85.15

Hold

18.60%

Upside

Reiterated

06/26/25

TD Cowen Sticks to Their Hold Rating for Merck & Company (MRK)

Geoff MeachamCiti

Citi

―

Hold

―

Reiterated

06/24/25

Citi Keeps Their Hold Rating on Merck & Company (MRK)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Tim AndersonBank of America Securities

Bank of America Securities

€84.3

Buy

17.41%

Upside

Reiterated

07/23/25

Analysts Offer Insights on Healthcare Companies: Icon (NASDAQ: ICLR), Merck & Company (NYSE: MRK) and Thermo Fisher (NYSE: TMO)We reiterate our Buy rating and $99 PO on Merck (MRK).

Daina GrayboschLeerink Partners

Leerink Partners

€97.93→€78.34

Buy

9.11%

Upside

Reiterated

07/18/25

Merck & Company: Buy Rating Backed by Growth Prospects in Cardiopulmonary and Infectious Disease Franchises

Evan SeigermanBMO Capital

BMO Capital

€69.83

Hold

-2.75%

Downside

Reiterated

07/17/25

Merck & Co. Hold Rating: Balancing Promising HIV Pipeline with Competitive Challenges and Market Uncertainty

Mohit BansalWells Fargo

Wells Fargo

€82.6

Hold

15.04%

Upside

Reiterated

07/17/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Harrow Health (NASDAQ: HROW), BridgeBio Pharma (NASDAQ: BBIO) and Merck & Company (NYSE: MRK)

Vamil DivanGuggenheim

Guggenheim

€91.97

Buy

28.09%

Upside

Reiterated

07/13/25

Guggenheim Sticks to Its Buy Rating for Merck & Company (MRK)

Trung HuynhUBS

UBS

€89.41

Buy

24.53%

Upside

Reiterated

07/10/25

UBS Sticks to Their Buy Rating for Merck & Company (MRK)

Tycho PetersonJefferies

Jefferies

€117.51→€120.07

Buy

67.22%

Upside

Reiterated

07/10/25

Jefferies Sticks to Its Buy Rating for Merck & Company (MRK)

Terence FlynnMorgan Stanley

Morgan Stanley

€84.3→€83.45

Hold

16.23%

Upside

Reiterated

07/10/25

Merck & Company's Strategic Acquisition of Verona Pharma: Balancing Long-Term Gains with Short-Term Financial Adjustments

Carter GouldCantor Fitzgerald

Cantor Fitzgerald

€72.38→€70.68

Hold

-1.56%

Downside

Reiterated

07/09/25

Cantor Fitzgerald Remains a Hold on Merck & Company (MRK)

Asad HaiderGoldman Sachs

Goldman Sachs

€84.3

Buy

17.41%

Upside

Reiterated

07/09/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Courtney BreenBernstein

Bernstein

―

Hold

―

Reiterated

07/08/25

Merck & Company (MRK) Gets a Hold from Bernstein

Chris SchottJ.P. Morgan

J.P. Morgan

€110.7

Buy

54.18%

Upside

Reiterated

07/07/25

Merck & Company: Strong Growth Potential and Favorable Risk/Return Profile Amidst Keytruda's Performance and Diverse Portfolio

Luisa HectorBerenberg Bank

Berenberg Bank

€85.15

Buy

18.60%

Upside

Reiterated

07/01/25

Berenberg Bank Reaffirms Their Buy Rating on Merck & Company (MRK)

Steve ScalaTD Cowen

TD Cowen

€85.15

Hold

18.60%

Upside

Reiterated

06/26/25

TD Cowen Sticks to Their Hold Rating for Merck & Company (MRK)

Geoff MeachamCiti

Citi

―

Hold

―

Reiterated

06/24/25

Citi Keeps Their Hold Rating on Merck & Company (MRK)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Merck & Company

1 Month

xxx

Success Rate

11/14 ratings generated profit

Average Return

+1.81%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 78.57% of your transactions generating a profit, with an average return of +1.81% per trade.

3 Months

xxx

Success Rate

10/14 ratings generated profit

Average Return

+2.64%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +2.64% per trade.

1 Year

Tim AndersonBank of America Securities

Success Rate

9/14 ratings generated profit

Average Return

+4.04%

reiterated a buy rating 6 days ago

Copying Tim Anderson's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +4.04% per trade.

2 Years

xxx

Success Rate

14/18 ratings generated profit

Average Return

+12.02%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 77.78% of your transactions generating a profit, with an average return of +12.02% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

6MK Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 6MK has received 24 Buy Ratings, 23 Hold Ratings, and 1 Sell Ratings. 6MK average Analyst price target in the past 3 months is 88.56.

Each month's total comprises the sum of three months' worth of ratings.

6MK Financial Forecast

6MK Earnings Forecast

Next quarter’s earnings estimate for 6MK is €1.72 with a range of €1.60 to €1.80. The previous quarter’s EPS was €1.89. 6MK beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.91% of the time in the same period. In the last calendar year 6MK has Preformed in-line its overall industry.

6MK Sales Forecast

Next quarter’s sales forecast for 6MK is €13.53B with a range of €13.23B to €14.30B. The previous quarter’s sales results were €13.29B. 6MK beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.40% of the time in the same period. In the last calendar year 6MK has Preformed in-line its overall industry.

6MK Stock Forecast FAQ

What is DE:6MK’s average 12-month price target, according to analysts?

Based on analyst ratings, Merck & Company’s 12-month average price target is 88.56.

What is DE:6MK’s upside potential, based on the analysts’ average price target?

Merck & Company has 23.34% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Merck & Company a Buy, Sell or Hold?

Merck & Company has a consensus rating of Moderate Buy, which is based on 9 buy ratings, 7 hold ratings and 0 sell ratings.

What is Merck & Company’s share price target?

The average share price target for Merck & Company is 88.56. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €119.98 ,and the lowest forecast is €69.78. The average share price target represents 23.34% Increase from the current price of €71.8.

What do analysts say about Merck & Company?

Merck & Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of Merck & Company?

To buy shares of DE:6MK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Merck & Company (6MK) Stock Forecast & Price Target

6MK Analyst Ratings

6MK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Merck & Company

6MK Analyst Recommendation Trends

6MK Financial Forecast

6MK Earnings Forecast

6MK Sales Forecast

6MK Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts